Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
about
Management of antipsychotic-related weight gainTherapeutic Use of Metformin in Prediabetes and Diabetes PreventionEfficacy of adjunctive treatments added to olanzapine or clozapine for weight control in patients with schizophrenia: a systematic review and meta-analysisPharmacological strategies to counteract antipsychotic-induced weight gain and metabolic adverse effects in schizophrenia: a systematic review and meta-analysis.Predictors and correlates for weight changes in patients co-treated with olanzapine and weight mitigating agents; a post-hoc analysis.Metformin for olanzapine-induced weight gain: a systematic review and meta-analysis.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.Effectiveness of medications used to attenuate antipsychotic-related weight gain and metabolic abnormalities: a systematic review and meta-analysisManagement of atypical antipsychotic drug-induced weight gain: focus on metformin.Can metformin undo weight gain induced by antipsychotics?Double-blind, randomized, clinical trial of metformin as add-on treatment with clozapine in treatment of schizophrenia disorder.Systematic Review and Meta-analysis of Pharmacological Interventions for Weight Gain from Antipsychotics and Mood Stabilizers.Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis.The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis.Interventions for the metabolic syndrome in schizophrenia: a reviewMetformin Prevents Fatty Liver and Improves Balance of White/Brown Adipose in an Obesity Mouse Model by Inducing FGF21Is Metabolic Syndrome On the Radar? Improving Real-Time Detection of Metabolic Syndrome and Physician Response by Computerized Scan of the Electronic Medical RecordDouble-blind, randomized trial comparing efficacy and safety of continuing olanzapine versus switching to quetiapine in overweight or obese patients with schizophrenia or schizoaffective disorder.Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.Antipsychotic induced weight gain in schizophrenia:mechanisms and management.Addressing cardiometabolic risk during treatment with antipsychotic medications.Schizophrenia, obesity, and antipsychotic medications: what can we do?Post-graduate CMEMetformin treatment of antipsychotic-induced dyslipidemia: an analysis of two randomized, placebo-controlled trialsMetformin: prevention and treatment of antipsychotic-induced weight gain.Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder.Metformin for weight reduction in non-diabetic patients on antipsychotic drugs: a systematic review and meta-analysis.Efficacy of metformin and topiramate in prevention and treatment of second-generation antipsychotic-induced weight gain.Metformin for obesity and glucose dysregulation in patients with schizophrenia receiving antipsychotic drugs.A systematic review of metformin to limit weight-gain with atypical antipsychotics.Can the therapeutic effects of temozolomide be potentiated by stimulating AMP-activated protein kinase with olanzepine and metformin?Metformin for treatment of antipsychotic-induced weight gain in a South Asian population with schizophrenia or schizoaffective disorder: A double blind, randomized, placebo controlled study.Association between antipsychotic treatment and leptin levels across multiple psychiatric populations: An updated meta-analysis.Augmentation of clozapine with another pharmacological agent: treatment for refractory schizophrenia in the 'real world'.Metformin ameliorates experimental-obesity-associated autoimmune arthritis by inducing FGF21 expression and brown adipocyte differentiation.The effect of reboxetine co-administration with olanzapine on metabolic and endocrine profile in schizophrenia patients.Swedish clinical guidelines--prevention and management of metabolic risk in patients with severe psychiatric disorders.Management of common adverse effects of antipsychotic medications
P2860
Q24610124-ED7AEF9C-2F89-4ED7-920C-FA4FB48DBF2DQ26822066-03FB49A0-0305-499C-B466-D2090B2F7A9DQ27691321-E7ECA599-8DF9-4EDC-9EAA-A228E3CE1FBBQ27692023-FD54189A-FC4D-4E15-BFE8-3B9F24DC9F46Q33423275-FB800B56-05C8-4653-82DC-381FF06E3492Q34161953-316E692E-DC62-4460-AF47-6CC3B0249F8FQ34315836-E4A40700-FC2F-4946-B1CB-62107313D9F8Q34661011-93020D77-68CB-42AE-AD08-4D76E1B86A07Q34983478-A8E1DF82-A622-4ED7-9185-055075F5FE64Q35247085-31850041-E71D-45ED-AE8F-00DC5E20A964Q35745299-1613A111-39F4-4223-9D97-C1E7670DD77FQ36034676-2788A57C-B534-4CED-B2F7-762FFDFABFDFQ36156730-E95B51A5-9BEC-4F49-9B3B-D9A244C37760Q36240230-40F9D114-3270-4456-B13B-9F6D4042B4B8Q36401248-CFA6A5DE-DEB0-417C-9DA0-1DAF25267A5FQ36556380-C6363D47-F636-4FCB-87A9-4C7B5602FE95Q36921831-200AE861-3274-4945-B6F5-D8C170413894Q37052769-652E356E-336D-4342-AC70-B9E8874FCCA4Q37095956-1F2DBAB9-A938-49AA-AB9C-A8BFAC478C39Q37160453-C0635AD6-44B8-4FC9-A929-83C77DC195E3Q37183591-375F783C-D30E-4052-8B23-365B45BE912BQ37226376-5825D4B3-7CF3-4810-AC7C-E90F5CAE3752Q37334124-2CB922CB-6AF4-4AF9-A9C9-42DE6F649B8DQ37364089-A2A291E8-D9E7-451A-A340-D9F76D643E01Q37378262-52BD4DA1-6FE9-41AC-A721-9A090C37A74AQ37416813-9C7A0993-9410-4E22-8196-584F599E78D2Q37676725-E3D5099F-334C-46BB-B5C3-10DDE6176CB6Q37710237-DF9C2F89-0391-4343-88E8-A1613CC6E370Q37822216-11A8C338-4640-4F3C-BB5F-427EB81CC388Q37854834-E31C7D40-C647-4912-88F6-EAAA4E5E658EQ39264163-06B99EEF-17B8-4966-902C-FA2792A9D3C7Q47351095-CC73643F-A7B7-47CD-AB16-C021B148255CQ47605999-34914DB5-D43C-411B-9734-5CF102A4482AQ48001560-41F8B93B-D2C9-4F18-977F-BBD46B7176A2Q49679549-1D4AE427-DB2D-4464-92E8-BDC34D494997Q50701935-E3A36BA1-EB61-4BAF-9516-BC60F2535430Q51847420-DCA9E322-41F9-4BDB-B8A4-3879203BCA08Q58760350-CED43A23-D4B6-408E-A891-F1C9A462BF22
P2860
Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@en
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@nl
type
label
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@en
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@nl
prefLabel
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@en
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@nl
P2093
P1476
Metformin as an adjunctive tre ...... ind, placebo-controlled trial.
@en
P2093
Adriana Dávila
Ana Serrano
Edgardo Carrizo
Enma Araujo de Baptista
Euderruh Uzcátegui
Lisette Connell
Marycelvia Uzcátegui
María A Gutiérrez
Mercedes Servigna
Nairy Rangel
P304
P356
10.1016/J.SCHRES.2007.03.029
P407
P577
2007-05-08T00:00:00Z